US Stock MarketDetailed Quotes

DMAC DiaMedica Therapeutics

Watchlist
  • 5.130
  • -0.110-2.10%
Trading Mar 20 13:07 ET
219.85MMarket Cap-8.55P/E (TTM)

DiaMedica Therapeutics Key Stats

DiaMedica Therapeutics Q4 2024 Earnings Date

Currency:USDMar 17, 2025

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
EPS
-0.17
-0.18
-<0.01
Miss Est.
-23.23%
-28.57%
-4.41%
Net Income
--
-7.90M
--
-53.07%
Strong Buy

Mar 20, 2025

DiaMedica Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CAD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 0.000--
--2025/Q1-- / 0.000--
Mar 17, 20252024/Q40.000 / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 0.000--
--2025/Q1-- / 0.000--
Mar 17, 20252024/Q40.000 / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--

Unlock Free Earnings Estimates

DiaMedica Therapeutics Earnings Reports

Read more

Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Mar 20, 2025

Strong Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data